IQVIA (NYSE:IQV) Stock Gets Price Target Bump from Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised IQVIA’s price target from $247 to $319 while maintaining an “outperform” rating, implying approximately 17.7% upside from the stock’s current price.
• Analyst sentiment remains positive, with IQVIA receiving a consensus “Moderate Buy” rating and an average price target of $257.75, supported by multiple recent target increases.
• IQVIA exceeded quarterly expectations, reporting $3.15 in earnings per share versus a $3.03 consensus estimate and $4.37 billion in revenue, up 8.7% year over year.

IQVIA (NYSE:IQV - Get Free Report) had its price objective boosted by investment analysts at Royal Bank Of Canada from $247.00 to $319.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Royal Bank Of Canada's target price would suggest a potential upside of 17.71% from the stock's current price.

Other equities analysts also recently issued research reports about the company. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Stifel Nicolaus lifted their price objective on IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Robert W. Baird upped their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. Morgan Stanley lifted their price target on shares of IQVIA from $240.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, September 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $257.75.

IQVIA Price Performance

NYSE:IQV opened at $271.01 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a 50-day moving average of $250.32 and a 200-day moving average of $203.63. IQVIA has a 52 week low of $154.50 and a 52 week high of $277.40. The company has a market capitalization of $44.61 billion, a price-to-earnings ratio of 33.62, a PEG ratio of 2.31 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA will post 11.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company's stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 15,581 shares of company stock valued at $3,796,021 over the last 90 days. Corporate insiders own 1.70% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IQV. Compass Financial Management LLC bought a new stake in IQVIA in the second quarter valued at about $27,000. Financial Freedom LLC acquired a new position in IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the first quarter worth $25,000. Elevation Wealth Partners LLC increased its position in shares of IQVIA by 218.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock valued at $30,000 after buying an additional 105 shares in the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of IQVIA during the fourth quarter worth about $35,000. Institutional investors and hedge funds own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.